Invited commentary. The role of tri-modality therapy in stage III nonsmall cell lung cancer (NSCLC) is highly controversial.
Kodama
Ken
K
Department of Thoracic Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3, Nakamichi, Higashinari-ku, Osaka, 537-8511 Japan. kodama-ke@mc.pref.osaka.jp
D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*